39600 EUREKA DR. SUITE 151
12 articles about AceLink Therapeutics
AceLink Therapeutics Announces Publication of Phase 1 Clinical Trial Data Evaluating AL01211 in Healthy Volunteers
AceLink Therapeutics, Inc. today announced that the findings from their Phase 1 study of AL01211 in healthy volunteers have been published in the peer-reviewed journal Clinical Pharmacology in Drug Development, a journal of the American College of Clinical Pharmacy.
AceLink Therapeutics, Inc., a clinical-stage biopharmaceutical company developing the next generation of oral substrate reduction therapies (SRTs), announced today that the first patient has been dosed with AL01211 in its Phase 2 trial in China in patients with Fabry disease.
AceLink Therapeutics, Inc. announced the opening of the first clinical trial site in China for its Phase 2, open‑label study of the safety, pharmacokinetics, pharmacodynamics and preliminary measures of physiological efficacy of AL01211 in males with classic Fabry disease who have not been previously treated with other Fabry disease therapies.
In the face of ever-changing circumstances, technological innovation remains the eternal driving force behind the long-term growth of biopharmaceutical companies.
AceLink Therapeutics Receives FDA Clearance to Initiate a Phase 2 Study of AL1211 in Patients with Fabry Disease
AceLink Therapeutics, Inc. today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase 2 clinical trial of its lead program, AL1211.
AceLink Therapeutics, Inc. today announced that Jerry Shen, Ph.D., Chief Executive Officer and Co-Founder of AceLink Therapeutics, will present at the World Orphan Drug Congress Conference.
AceLink Therapeutics, Inc. today announced the appointment of Pedro Huertas, M.D., Ph.D., as Chief Medical Officer (CMO).
Recently, 6 of Viva's portfolio companies have achieved significant results and progress: Mediar and QurAlis have successfully completed financing, while AmacaThera, AceLink, Basking, and TechnoDerma have made smooth progress in their R&D pipelines.
AceLink Therapeutics, Inc. (AceLink), an innovative biopharmaceutical company developing transformative therapies for genetic diseases, today presented data on the development of AL00804, a novel brain penetrant glucosylceramide synthase inhibitor, to treat Gaucher disease and other neuronopathic glycosphingolipid (GSL) storage diseases.
AceLink Therapeutics, Inc. today presented positive data from a Phase 1 trial evaluating the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AL01211 in healthy volunteers.
AceLink Therapeutics to present two posters on Fabry Disease and Gaucher Disease at 2023 WORLD Symposium
AceLink Therapeutics, Inc. announced that the company will present two abstracts featuring the development of AL01211 to treat Fabry disease and AL00804 to treat Gaucher disease and other neuronopathic glycosphingolipid storage diseases at the 19th Annual World Symposium Conference, being held in Orlando, Florida, from February 22-26, 2023.
AceLink Therapeutics Receives Orphan Drug Designation for its Novel GCS Inhibitor AL01211 for the Treatment of Fabry Disease
AceLink Therapeutics, Inc. (AceLink), an innovative biopharmaceutical company developing transformative therapies for genetic diseases, today announced it has received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for AL01211 as a treatment for Fabry disease.